Literature DB >> 18537788

Superiority, equivalence, and non-inferiority trials.

Emmanuel Lesaffre1.   

Abstract

When the aim of the randomized controlled trial (RCT) is to show that one treatment is superior to another, a statistical test is employed and the trial (test) is called a superiority trial (test). Often a nonsignificant superiority test is wrongly interpreted as proof of no difference between the two treatments. Proving that two treatments are equal in performance is impossible with statistical tools; at most, one can show that they are equivalent. In an equivalence trial, the statistical test aims at showing that two treatments are not too different in characteristics, where "not too different" is defined in a clinical manner. Finally, in a non-inferiority trial, the aim is to show that an experimental treatment is not (much) worse than a standard treatment. In this report, the three types of trials are compared, but the main focus is on the non-inferiority trial. Special attention is paid to the practical implications when setting up a non-inferiority trial. Illustrations are taken from a clinical trial in osteoarthritis and from thrombolytic research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537788

Source DB:  PubMed          Journal:  Bull NYU Hosp Jt Dis        ISSN: 1936-9719


  62 in total

Review 1.  Generic and therapeutic substitutions: are they always ethical in their own terms?

Authors:  Mubarak AlAmeri; Miran Epstein; Atholl Johnston
Journal:  Pharm World Sci       Date:  2010-12

2.  How to calculate sample size in randomized controlled trial?

Authors:  Baoliang Zhong
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

Review 3.  [Placebo response: in studies on pain and under other clinical conditions].

Authors:  K Weimer; B Horing; S Klosterhalfen; P Enck
Journal:  Schmerz       Date:  2011-06       Impact factor: 1.107

Review 4.  Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials.

Authors:  Patrick Vavken
Journal:  Clin Orthop Relat Res       Date:  2011-01-19       Impact factor: 4.176

Review 5.  Use of Mortality as an Endpoint in Noninferiority Trials May Lead to Ethically Problematic Conclusions.

Authors:  Andrew M Hersh; Robert J Walter; Scott K Abberegg
Journal:  J Gen Intern Med       Date:  2019-02-12       Impact factor: 5.128

6.  Bayesian data analysis for newcomers.

Authors:  John K Kruschke; Torrin M Liddell
Journal:  Psychon Bull Rev       Date:  2018-02

7.  The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective.

Authors:  John K Kruschke; Torrin M Liddell
Journal:  Psychon Bull Rev       Date:  2018-02

8.  Obstructive Sleep Apnea and Stroke.

Authors:  Anupama Gupta; Garima Shukla
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

9.  Biomechanical outcomes after bioenhanced anterior cruciate ligament repair and anterior cruciate ligament reconstruction are equal in a porcine model.

Authors:  Patrick Vavken; Braden C Fleming; Ashley N Mastrangelo; Jason T Machan; Martha M Murray
Journal:  Arthroscopy       Date:  2012-01-20       Impact factor: 4.772

10.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.